Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 147 participants.
Also called NCT07901595
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 147 participants
- Sponsor
- Paulex Bio Inc.
- Registry
-
NCT07901595
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07901595. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2027-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
- Condition
- Healthy Volunteers and Diabetes Participants
- Intervention (Drug)
- PAL-119
- Intervention (Drug)
- Placebo
- Lead sponsor
- Paulex Bio Inc.
Record details
- Record id
cardio:ct-nct07901595- Content hash
423758ebf1ef726a270a477f69ef50026db3e51ebd06ac96c3bd691f70aceab6